MOLOGEN AG / Key word(s): Capital Increase 05.02.2014 21:47 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- With the approval of the Supervisory Board and on the basis of the registered authorized capital the Management Board of MOLOGEN AG decided today to increase the share capital against cash contributions without subscription rights of the shareholders from currently EUR 15,419,512 to EUR 16,960,756 Euros by issuing up to 1,541,244 new no-par value bearer shares with dividend rights from 1st January 2013. The proceeds from the capital increase will be used to further strengthen the equity base and in particular to finance the development of the product pipeline and the necessary ongoing research operations. The new shares will be offered to European qualified investors in the context of a private placement. The placement starts today, 5 February 2014, and is expected to be completed tomorrow, 6 February 2014. MOLOGEN AG will set the issue price after the completion of a bookbuilding process and depending on the market situation at a discount of up to 5 per cent on the volume weighted average share price in Xetra trading during the last five trading days or on the in XETRA trading lastly determined stock price. The new shares shall be admitted to trading, without prospectus requirement, in the sub-segment of the regulated market with further post-admission obligations (Prime Standard) of the Frankfurt Stock Exchange. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: DISCLAIMER This document is not an offer of securities for sale in the United States of America. The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the 'Securities Act') and may not be offered or sold absent registration or an exemption from registration under the Securities Act. The Issuer does not intend to register any portion of the offering in the United States of America or to conduct a public offering of the securities in the United States of America, Canada, Australia, Japan or South Africa. About MOLOGEN AG MOLOGEN AG is a publicly listed biotechnology company headquartered in Berlin and specializes in the research and clinical development of innovative drugs in the fields of oncology and infectious diseases. One of the company's most important product candidates is the DNA immunomodulator MGN1703, which is being clinically developed for colorectal cancer and lung cancer. The cell-based cancer therapy MGN1601 for the treatment of renal cancer is also currently at the stage of clinical development.â¨â¨With unique, patented technologies and innovative product developments, MOLOGEN is one of the leading biotechnology companies in the fields of DNA medicine and cell-based therapies.â¨â¨MOLOGEN AG shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange. www.mologen.com Memberships in associations: Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI) MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. MOLOGEN AG PRESS SERVICE: Prof. Peter W. Hübner Head of Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 huebner@mologen.com INVESTOR RELATIONS: Jörg Petraà Tel: +49 - 30 - 84 17 88 - 13 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com External Investor Relations: Kirchhoff Consult AG Sebastian Bucher Tel: +49 - 40 - 60 91 86 - 18 Fax: +49 - 40 - 60 91 86 - 16 sebastian.bucher@kirchhoff.de 05.02.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: MOLOGEN AG FabeckstraÃe 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: info@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: MOLOGEN AG resolves capital increase from authorized capital
| Source: EQS Group AG